Home › Small Cell Lung Cancer › Ohio
Small Cell Lung Cancer clinical trials in Ohio
28 studies for Small Cell Lung Cancer are looking for participants at sites in Ohio.
Cities in Ohio
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
- University Hospitals Cleveland Medical Center /ID# 277556, Cleveland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07155174Prospective Multiomic Analysis in Small-Cell Lung Cancer
- Ohio State University Comprehensive Cancer Center, Columbus
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07795411The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- The Cleveland Clinic Taussig Cancer Center, Cleveland
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
- University Hospitals Cleveland Medical Center, Cleveland
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07226999A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
- GSK Investigational Site, Canton
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07099898DESTINY-PANTUMOUR04
- Research Site, Canton
- Research Site, Maumee
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
- Oncology Hematology Care - Fairfield /ID# 280641, Fairfield
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07365241Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
- University Hospitals Cleveland Medical Center, Cleveland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07278479A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
- University Hospitals Cleveland Medical Center, Cleveland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT07325136A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
- Cleveland Clinic - Akron General Medical Center, Akron
- University Hospitals Cleveland Medical Center, Cleveland
- Cleveland Clinic - Fairview Hospital Molly Pavilion, Cleveland
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT07218146A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- Oncology Hematology Care, Cincinnati
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06646276Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Cleveland Clinic - Akron General Hematology & Oncology, Akron
- Cleveland Clinic Mercy Hospital Cancer Center, Canton
- The Christ Hospital Cancer Center, Cincinnati
- and 5 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 1, 2026 · NCT06712355Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer
- Ohio State Univerity, Columbus
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07057791A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
- Cleveland Clinic Taussig Cancer Institute Case Comprehensive Cancer Center, Cleveland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT06892548A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
- Oncology Hematology Care Clinical Trials, Cincinnati
- University Hospital - Cleveland Medical Center, Cleveland
- Zangmeister Cancer Center, Columbus
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT06095505A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- The Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT05592626A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Cleveland Clinic Mercy Hospital, Canton
- Oncology/Hematology Care Clinical Trials, Llc, Cincinnati
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT06203210Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer
- Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 6, 2026 · NCT07423585A Study of LY4175408 in Participants With Advanced Cancer
- The Ohio State University (OSU) Wexner Medical Center, Columbus
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT07046923Tempus Small Cell Lung Cancer Observational Study (Sculptor)
- TriHealth Cancer Institute, Cincinnati
- Ohio State University, Columbus
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jun 15, 2026 · NCT05257551Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
- Cleveland Clinic, Cleveland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 8, 2026 · NCT05363280Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
- Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 8, 2026 · NCT04919382Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
- Aultman Health Foundation, Canton
- Miami Valley Hospital South, Centerville
- Miami Valley Hospital, Dayton
- and 5 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 30, 2026 · NCT06769126Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- Cleveland Clinic, Cleveland
- Taylor Cancer Research Center, Maumee
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Feb 18, 2026 · NCT07030257VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Taylor Cancer Research Center (site 204), Maumee
RecruitingPhase 1/2
Ages 18 to 80 · All sexes · Updated Dec 11, 2025 · NCT03556228A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 138, Canton
- Research Site 113, Cincinnati
- Research Site 131, Dayton
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 21, 2025 · NCT05914116A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
- Case Comprehensive Cancer Center, Cleveland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2025 · NCT06805825A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer
- Zelgen Site 101, Canton
- Zelgen Site 104, Cleveland
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Aug 6, 2025 · NCT06592638From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.